BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29028854)

  • 41. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
    Beltraminelli H
    Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new nail in the CTCL coffin.
    Lessin SR
    J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic.
    Chang MB; Weaver AL; Brewer JD
    Int J Dermatol; 2014 Aug; 53(8):966-70. PubMed ID: 24134412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016.
    Keto J; Hahtola S; Linna M; Väkevä L
    BMC Health Serv Res; 2021 Feb; 21(1):166. PubMed ID: 33618714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous T-cell lymphoma (mycosis fungoides).
    Lorincz AL
    Lancet; 1996 Mar; 347(9005):871-6. PubMed ID: 8622396
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of mycosis fungoides and Sézary syndrome].
    Nicolay JP; Assaf C
    Hautarzt; 2017 Sep; 68(9):702-710. PubMed ID: 28770285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL.
    Brazel D; Pinter-Brown L
    Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):401-409. PubMed ID: 37061415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.
    Kuzel TM; Roenigk HH; Rosen ST
    J Clin Oncol; 1991 Jul; 9(7):1298-313. PubMed ID: 2045869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
    Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
    J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutaneous Lymphomas - Part I: Mycosis Fungoides, Sézary Syndrome, and CD30
    Pujol RM; Gallardo F
    Actas Dermosifiliogr (Engl Ed); 2021 Jan; 112(1):14-23. PubMed ID: 32896500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mycosis fungoides and Sézary syndrome.
    Hwang ST; Janik JE; Jaffe ES; Wilson WH
    Lancet; 2008 Mar; 371(9616):945-57. PubMed ID: 18342689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Leroy S; Dubois S; Tenaud I; Chebassier N; Godard A; Jacques Y; Dréno B
    Br J Dermatol; 2001 May; 144(5):1016-23. PubMed ID: 11359391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How we treat mycosis fungoides and Sézary syndrome.
    Khan N; Noor SJ; Horwitz S
    Clin Adv Hematol Oncol; 2021 Sep; 19(9):573-581. PubMed ID: 34495021
    [No Abstract]   [Full Text] [Related]  

  • 57. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
    Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
    Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides".
    Zhang Y; Seminario-Vidal L; Cohen L; Hussaini M; Yao J; Rutenberg D; Kim Y; Giualiano A; Robinson LA; Sokol L
    Front Cell Infect Microbiol; 2022; 12():850509. PubMed ID: 35656034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of primary cutaneous T-cell lymphoma in Norway.
    Saunes M; Nilsen TI; Johannesen TB
    Br J Dermatol; 2009 Feb; 160(2):376-9. PubMed ID: 18808419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Mycosis fungoides and Sézary syndrome, so-called cutaneous T-cell lymphoma].
    Rupniewska ZM
    Postepy Hig Med Dosw; 1982; 36(4):231-49. PubMed ID: 6764803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.